Feb 16, 2021
InMed Announces Closing of US$4.5 Million Private Placement
Feb 11, 2021
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results
Feb 05, 2021
InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results
Feb 05, 2021
InMed Announces US$4.5 Million Private Placement
Jan 19, 2021
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe
Jan 05, 2021
InMed to Participate at Virtual Conferences in January 2021
Dec 03, 2020
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids
Nov 25, 2020
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Nov 24, 2020
InMed Announces Election of Directors
Nov 18, 2020
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics
Nov 16, 2020
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering
Nov 13, 2020
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results
Nov 12, 2020
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"
Nov 05, 2020
InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020
Nov 04, 2020
InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020
Sep 24, 2020
InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Sep 22, 2020
InMed Pharmaceuticals Announces Additional IntegraSyn(TM) Patent Filing
Sep 08, 2020
InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update
Sep 02, 2020
InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020
Jul 07, 2020
InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755